Analyst Price Target is $34.20
▲ +236.28% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Codexis in the last 3 months. The average price target is $34.20, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 236.28% upside from the last price of $10.17.
Current Consensus is
The current consensus among 5 investment analysts is to buy stock in Codexis. This Buy consensus rating has held steady for over two years.
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.